question · intermediate · partly written
Does matching therapy to a child's leukemia genome improve outcomes?
Whether treating relapsed pediatric leukemia with the drug that matches its alteration helps children, which no study read has tested against unmatched care.
Also called: LEAP matched therapy outcomes
What the figures mean
The 77% in the registry, the 18% of recommendations at the two highest evidence tiers in the paper, and the 17 treated patients answer different questions. None of them is a response rate. 12
Reported, not yet replicated
Observation
What is known
What is not
Whether any remission was caused by the matched drug: per-patient vignettes show remissions on matched drugs given alongside chemotherapy or transplant, and no unmatched comparison exists. 1
Our inference
What would settle it
Outcomes for the full registry cohort, with a comparison group, and a response definition fixed in advance. 2
Our inference
Still open here
- How many of the 338 enrolled patients received matched therapy, and with what outcome?
Not yet written: Hypotheses, What is missing, Who works on it.
Linked from
Sources
- Pikman Y, et al. Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium (Cancer Discovery 2021). (2021). paper; opened 2026-11-17 all records citing this
- ClinicalTrials.gov NCT02670525: Matched Targeted Therapy for High-Risk Leukemias and MDS. (2026). database, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Kind
- big-open
- Register
- open-question
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/questions/matched-therapy-benefit-pediatric-leukemia.json